Programmed electrical stimulation in human iPSC-derived cardiomyocytes reveals mechanisms of lethal arrhythmias in Calcium Release Deficiency Syndrome

This study establishes the first human iPSC-derived cardiomyocyte model of Calcium Release Deficiency Syndrome (CRDS) that recapitulates clinically observed lethal arrhythmias triggered by specific electrical stimulation protocols, revealing that these events arise from early afterdepolarization-driven re-entry during electrically vulnerable states and can be suppressed by flecainide.

The Gist

The Big Picture: A "Silent" Heart Condition

Imagine your heart is a high-performance engine that needs to pump blood rhythmically. Usually, when this engine misfires, it's because it's running too hot (too much adrenaline from exercise or stress). Doctors can easily spot this by making patients run on a treadmill.

However, there is a rare, dangerous condition called Calcium Release Deficiency Syndrome (CRDS). In this condition, the heart's "fuel pump" (a protein called RyR2) is broken, but in a very specific way: it's too tight. It doesn't leak fuel when it should, but it gets stuck and then suddenly dumps a massive amount of fuel all at once.

The scary part? This doesn't happen when you run. It happens when the heart is resting or just after a sudden stop. Because standard stress tests (treadmills) don't catch this, patients with CRDS often go undiagnosed until they suffer a sudden, fatal heart attack.

The Problem: We Couldn't Study It in a Lab

For a long time, scientists couldn't study CRDS in a lab because:

1. It's rare.
2. You can't easily test dangerous heart rhythms on human patients.
3. Previous lab models (using mouse cells or immature human cells) didn't behave like the real human heart. They acted like the "hot engine" (CPVT) instead of the "stuck engine" (CRDS).

The Solution: Building a "Mini-Heart" in a Dish

The researchers in this paper did something groundbreaking. They took skin cells from a patient with CRDS, turned them back into stem cells (like biological "clay"), and then sculpted them into heart muscle cells (hiPSC-CMs).

Crucially, they didn't just make a few loose cells; they grew a thin sheet of heart tissue (a monolayer) and made sure these cells were "metabolically mature." Think of this as taking a toddler and raising them to be a fully grown adult athlete. This maturity was key because immature cells behave differently than adult human hearts.

They created two versions of this mini-heart:

• The Control: A healthy version.
• The Mutant: A version with the specific broken RyR2 gene (E4146D) found in the patient.

The Experiment: The "Shock and Pause" Test

Since the heart doesn't misfire during exercise, the researchers had to invent a new way to trigger the problem in the lab. They used a "Programmed Electrical Stimulation" protocol, which they call LBLPS.

The Analogy: The Swing Set
Imagine pushing a child on a swing.

1. Long Burst (LB): You push the swing very fast, 25 times in a row. This tires out the swing's mechanism.
2. Long Pause (LP): You stop pushing completely and let the swing hang still for a long time. This is like the heart resting after a race.
3. Short-Coupled Stimulus (S): Just as the swing is about to stop moving, you give it one tiny, perfectly timed nudge.

What Happened?

• Healthy Hearts: The nudge did nothing. The swing kept moving normally.
• CRDS Hearts: The tiny nudge caused the swing to go wild. The heart cells misfired, creating a chaotic rhythm called re-entry.

The Discovery: Why It Goes Wrong

The researchers used high-speed cameras to watch the electricity and calcium moving through the heart tissue. They found the "smoking gun":

1. The "Stuck" Valve: Because the RyR2 pump is broken, calcium builds up inside the heart cell during the fast pushing (the Long Burst).
2. The Big Dump: When the pause happens, the cell is overloaded with calcium.
3. The Spark (EAD): When the tiny nudge comes, the cell tries to fire, but because it's so overloaded, it gets a "static shock" (called an Early Afterdepolarization or EAD).
4. The Loop: This shock causes the heart to beat early and erratically. Because the heart tissue is now uneven (some parts are ready to fire, others aren't), the electrical signal gets stuck in a loop, circling around like a car driving in circles on a roundabout. This is re-entrant arrhythmia, which leads to cardiac arrest.

Key Finding: The heart didn't just misfire randomly; it misfired because the "timing" of the cells became messy (discordant), creating a perfect storm for a loop to form.

The Good News: A Potential Cure

The researchers tested a common heart medication called Flecainide.

• The Result: When they added Flecainide to the mini-hearts, the chaotic loops stopped. The "stuck engine" was fixed, and the heart returned to a normal rhythm.
• Why it matters: This confirms that Flecainide, which is already used for other heart conditions, could be a life-saving treatment for CRDS patients who currently have no good options.

Summary

This paper is a major breakthrough because:

1. It built the first accurate human model of this rare, deadly disease.
2. It figured out the mechanism: The heart doesn't fail from stress; it fails from a "stuck" calcium pump that causes a chaotic loop after a pause.
3. It found a treatment: The drug Flecainide successfully stopped the dangerous loops in the lab.

In a nutshell: Scientists finally built a realistic "mini-heart" that mimics a rare, silent killer. They discovered that this heart goes haywire when it's overfilled with calcium and then gets a tiny nudge, causing a dangerous electrical loop. Fortunately, they found a drug that can stop the loop, offering hope for patients who were previously undiagnosed and untreatable.

Technical Summary

1. Problem Statement

Calcium Release Deficiency Syndrome (CRDS) is a recently identified inherited channelopathy caused by loss-of-function (LOF) variants in the cardiac ryanodine receptor (RyR2). Unlike Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), which is caused by gain-of-function (GOF) RyR2 variants and triggered by adrenergic stress (exercise), CRDS patients often present with lethal ventricular arrhythmias that are not reproduced by exercise stress testing.

• Clinical Challenge: CRDS is frequently misdiagnosed or underdiagnosed because standard diagnostic tools fail to unmask the arrhythmias. The specific triggers and electrophysiological mechanisms in human tissue remain poorly understood.
• Research Gap: While mouse models have shown that CRDS arrhythmias can be induced by Programmed Electrical Stimulation (PES) protocols (specifically Long-Burst, Long-Pause, Short-coupled extra-stimulus or LBLPS), no human in vitro model existed that could recapitulate these tissue-level arrhythmias or the unique post-pacing repolarization abnormalities seen in patients. Previous human iPSC-CM models for RyR2 LOF variants failed to consistently reproduce the clinical phenotype, often showing delayed afterdepolarizations (DADs) instead of the suspected early afterdepolarizations (EADs).

2. Methodology

The study utilized a combination of genome editing, metabolic maturation, and high-resolution electrophysiological mapping to create a robust human disease model.

• Cell Model Generation:
  • Source: Human induced pluripotent stem cells (hiPSCs) from a healthy donor.
  • Editing: CRISPR-Cas9 was used to introduce the heterozygous RyR2-E4146D variant (a known LOF variant linked to CRDS, LQTS, and short-coupled Torsades de Pointes) into the hiPSC genome. An isogenic control line was generated.
  • Maturation: The derived cardiomyocytes (hiPSC-CMs) underwent a 3-week metabolic maturation protocol (fatty acid-rich media) to enhance physiological maturity and excitation-contraction coupling.
• Tissue Preparation:
  • Cells were plated at high density to form 2D confluent monolayers, allowing for the study of tissue-level conduction and re-entry, rather than just single-cell behavior.
• Electrophysiological Characterization:
  • High Spatiotemporal Optical Mapping (OM): Dual-imaging of membrane voltage ($V_m$) and intracellular calcium ($Ca^{2+}$) using FluoVolt and Calbryte 630 dyes. This allowed for simultaneous visualization of action potential duration (APD) and calcium transient dynamics at high frame rates (up to 277 fps for Ca$^{2+}$).
  • Programmed Electrical Stimulation (PES): The team applied clinically validated protocols:
    • Long Burst (LB): Rapid pacing (2–5 Hz) to induce alternans.
    • Long Pause (LP): A pause (1000–1500 ms) following the burst.
    • Short-Coupled Extra Stimulus (S2): A premature stimulus delivered after the pause to mimic an EAD.
    • LBLPS: The full sequence (LB + LP + S2).
  • Multielectrode Arrays (MEA): Used to validate field potential duration and conduction velocity.
  • Pharmacology: Testing of Flecainide (1 µM) to assess therapeutic efficacy.
• Molecular Validation:
  • RNA sequencing, Mass Spectrometry (proteomics), and Immunocytochemistry were used to confirm RyR2 expression, subcellular localization (Z-disc alignment), and the absence of compensatory changes in other excitation-contraction proteins.

3. Key Contributions

1. First Human CRDS Model: This study presents the first hiPSC-CM model for CRDS that successfully recapitulates the tissue-level arrhythmias and post-pacing repolarization abnormalities observed clinically, without requiring $\beta$-adrenergic stimulation.
2. Mechanistic Insight into EADs: The study definitively links RyR2 LOF to Early Afterdepolarization (EAD)-driven triggered activity and re-entrant conduction, resolving previous inconsistencies in the field where DADs were often observed in less mature models.
3. Validation of LBLPS Protocol: It demonstrates that the LBLPS protocol is a reliable trigger for arrhythmias in human CRDS tissue, validating its use as a diagnostic and research tool.
4. Drug Screening Platform: The model successfully identified Flecainide as an effective suppressor of arrhythmia inducibility, establishing a framework for future drug and gene therapy development.

4. Key Results

• Baseline Phenotype:

  • At baseline (spontaneous beating or 1 Hz pacing), E4146D+/- monolayers showed no arrhythmias, similar to controls.
  • However, E4146D+/- monolayers exhibited a significantly reduced conduction velocity (CV) compared to controls, suggesting a link between RyR2 function and tissue conduction.
  • Single cells showed irregular spontaneous calcium transients (mostly late-systolic), but these did not translate to tissue-level arrhythmias at rest.

• Response to Rapid Pacing (Long Burst):

  • E4146D+/- monolayers had a lower threshold for APD and Ca$^{2+}$ alternans (median 2 Hz vs. 2.5 Hz in controls).
  • Crucially, E4146D+/- tissues were more prone to transitioning from spatially concordant to discordant alternans. This discordance created spatial dispersion of repolarization, leading to unidirectional conduction blocks and re-entrant arrhythmias in 53.6% of E4146D+/- monolayers (0% in controls).

• Post-Pacing Repolarization Abnormality (Long Pause):

  • Following a Long Burst and Long Pause, E4146D+/- monolayers (35.7% of samples) displayed a hallmark CRDS phenotype: the first spontaneous beat showed prolonged APD90, larger Ca$^{2+}$ transient amplitude, and increased spatial dispersion of repolarization. This mimics the "abnormal T-wave" and prolonged QT seen in patients.

• Arrhythmia Induction (LBLPS):

  • Application of the full LBLPS protocol induced short-coupled, non-sustained ventricular tachycardia (NSVT)-like beats in 23.8% of E4146D+/- monolayers (0% in controls).
  • These arrhythmias were characterized by EAD-driven triggered activity originating from ectopic sites, leading to re-entrant conduction patterns.
  • Arrhythmias were also observed spontaneously during the Long Burst phase if discordant alternans occurred, suggesting that electrical vulnerability (dispersion of repolarization) is the critical substrate.

• Therapeutic Response:

  • Flecainide significantly reduced the number of cells with irregular calcium transients.
  • On the tissue level, Flecainide suppressed the transition to discordant alternans and completely abolished the inducibility of both spontaneous and LBLPS-triggered arrhythmias.

5. Significance

• Diagnostic Advancement: The study validates the LBLPS protocol as a mechanism for unmasking CRDS in human tissue, supporting its clinical use (e.g., in the DIAGNOSE-CRDS trial) for patients who are negative on standard exercise stress tests.
• Pathophysiological Clarity: It clarifies that CRDS arrhythmias are driven by EADs and re-entry due to repolarization heterogeneity and conduction slowing, rather than the DADs seen in CPVT. This distinction is vital for understanding the disease mechanism.
• Translational Platform: The developed hiPSC-CM model serves as a robust New Approach Method (NAM) for:
  • Studying complex, tissue-level arrhythmias (like short-coupled VF) that are difficult to model otherwise.
  • Personalized drug screening (demonstrated here with Flecainide).
  • Developing gene therapies for RyR2-related channelopathies.
• Clinical Relevance: The findings support the clinical observation that CRDS patients can be managed with Flecainide, providing a mechanistic basis for this treatment strategy.

In summary, this paper bridges the gap between mouse models and human clinical presentation of CRDS, providing the first human in vitro evidence that programmed electrical stimulation can unmask lethal, re-entrant arrhythmias driven by EADs in RyR2 LOF tissue, and demonstrating the efficacy of Flecainide in suppressing these events.